Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018699 | 0.98 | PTPN11 (0.47) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL18712240 | 0.94 | PTPN11 (0.44) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL3007588 | 0.94 | PTPN11 (0.46) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL13739617 | 0.91 | PTPN11 (0.41) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL3016768 | 0.90 | HPGD (0.44) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL13757141 | 0.89 | PTPN11 (0.51) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL16840411 | 0.87 | PTPN11 (0.45) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL13737683 | 0.86 | PTPN11 (0.40) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL16840419 | 0.86 | PTPN11 (0.44) | PTPN11CA1CA2TDP1CA12 | |
| SCHEMBL10412465 | 0.85 | PTPN11 (0.60) | PTPN11CA1CA2TDP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171400-A1 | AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-BIOTIX THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12227475-B2 | Aza-heterocyclyl carboxamide and related compounds and their use in treating medical conditions | X-BIOTIX THERAPEUTICS, INC. | 2025-02-18 | — | — | US | disclosed |
| US-12103904-B2 | Benzoylglycine derivatives and methods of making and using same | DUKE UNIVERSITY (US) | 2024-10-01 | — | — | US | disclosed |
| EP-4286001-A2 | BENZOYLGLYCINE DERIVATIVES AND METHODS OF MAKING AND USING SAME | Duke University (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3448375-B1 | BENZOYLGLYCINE DERIVATIVES AND METHODS OF MAKING AND USING SAME | UNIV DUKE (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230139502-A1 | AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-BIOTIX THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20210206715-A1 | Benzoylglycine Derivatives and Methods of Making and Using Same | DUKE UNIVERSITY (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210206715-A1 | Benzoylglycine Derivatives and Methods of Making and Using Same | DUKE UNIVERSITY (US) | 2021-07-08 | — | — | US | disclosed |
| US-11034649-B2 | Benzoylglycine derivatives and methods of making and using same | DUKE UNIVERSITY (US) | 2021-06-15 | — | — | US | disclosed |
| US-11034649-B2 | Benzoylglycine derivatives and methods of making and using same | DUKE UNIVERSITY (US) | 2021-06-15 | — | — | US | disclosed |
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9073821-B2 | Hydroxamic acid derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9073821-B2 | Hydroxamic acid derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9073821-B2 | Hydroxamic acid derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130072677-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| US-20130072677-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| EP-2562155-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-02-27 | — | — | EP | disclosed |
| EP-2562155-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206715-A1 | Benzoylglycine Derivatives and Methods of Making and Using Same | B3GAT3, GLO1, GLMN | PTPN11 2914/4885CA1 4378/4885CA2 2925/4885 |
| US-20230139502-A1 | AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | AADAC, AZI2, CBX7 | PTPN11 768/4885CA1 3543/4885CA2 1519/4885 |
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | LCT, AGXT, HDAC9 | PTPN11 926/4885CA1 2188/4885CA2 294/4885 |
| US-11034649-B2 | Benzoylglycine derivatives and methods of making and using same | B3GAT3, GLO1, GLMN | PTPN11 2914/4885CA1 4378/4885CA2 2925/4885 |
| US-12227475-B2 | Aza-heterocyclyl carboxamide and related compounds and their use in treating medical conditions | AADAC, AZI2, CBX7 | PTPN11 768/4885CA1 3543/4885CA2 1519/4885 |
| US-20250171400-A1 | AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | AADAC, AZI2, CBX7 | PTPN11 768/4885CA1 3543/4885CA2 1519/4885 |
| US-12103904-B2 | Benzoylglycine derivatives and methods of making and using same | B3GAT3, GLO1, GLMN | PTPN11 2914/4885CA1 4378/4885CA2 2925/4885 |
| US-20130072677-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | LCT, AGXT, HDAC9 | PTPN11 926/4885CA1 2188/4885CA2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.